| __timestamp | Alpine Immune Sciences, Inc. | Eli Lilly and Company |
|---|---|---|
| Wednesday, January 1, 2014 | 2287709 | 6620800000 |
| Thursday, January 1, 2015 | 6844000 | 6533000000 |
| Friday, January 1, 2016 | 8586000 | 6452000000 |
| Sunday, January 1, 2017 | 6079000 | 6588100000 |
| Monday, January 1, 2018 | 8362000 | 5975100000 |
| Tuesday, January 1, 2019 | 9467000 | 6213800000 |
| Wednesday, January 1, 2020 | 10899000 | 6121200000 |
| Friday, January 1, 2021 | 14560000 | 6431600000 |
| Saturday, January 1, 2022 | 17968000 | 6440400000 |
| Sunday, January 1, 2023 | 22222000 | 6941200000 |
Unleashing insights
In the ever-evolving pharmaceutical landscape, understanding the financial strategies of industry giants and emerging players is crucial. Eli Lilly and Company, a stalwart in the sector, has consistently demonstrated robust financial management. From 2014 to 2023, their Selling, General, and Administrative (SG&A) expenses have shown a steady trend, peaking at approximately $6.94 billion in 2023. This represents a modest increase of about 5% over the decade, reflecting strategic investments in marketing and administration.
In contrast, Alpine Immune Sciences, Inc., a burgeoning biotech firm, has exhibited a more dynamic trajectory. Their SG&A expenses surged nearly tenfold, from around $2.29 million in 2014 to $22.22 million in 2023. This dramatic rise underscores their aggressive expansion and investment in growth.
These trends highlight the differing strategies of established and emerging companies in navigating the competitive pharmaceutical industry.
Eli Lilly and Company and Novo Nordisk A/S: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Eli Lilly and Company vs Neurocrine Biosciences, Inc. Trends and Insights
Selling, General, and Administrative Costs: Eli Lilly and Company vs Verona Pharma plc
Comparing SG&A Expenses: Eli Lilly and Company vs CRISPR Therapeutics AG Trends and Insights
Eli Lilly and Company vs Amicus Therapeutics, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Eli Lilly and Company vs MorphoSys AG
Eli Lilly and Company vs Supernus Pharmaceuticals, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Summit Therapeutics Inc. vs Alpine Immune Sciences, Inc.
Comparing SG&A Expenses: Alkermes plc vs Alpine Immune Sciences, Inc. Trends and Insights
Opthea Limited vs Alpine Immune Sciences, Inc.: SG&A Expense Trends
Alpine Immune Sciences, Inc. vs Bausch Health Companies Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Alpine Immune Sciences, Inc. vs Viridian Therapeutics, Inc. Trends and Insights